Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients.
BACKGROUND
The aim of this study was to identify prognostic factors for local and systemic failure after isolated hepatic perfusion (IHP) with 200 mg melphalan in patients with colorectal liver metastases.


METHODS
Hundred and fifty-four patients were selected for IHP and underwent laparotomy. Patients were monitored for response, toxicity and survival. Univariate and multivariate analyses were carried out to identify prognostic factors for hepatic response and progression-free and overall survival.


RESULTS
Hepatic response rate was 50% with a median progression-free and overall survival of, respectively, 7.4 and 24.8 months. In multivariate analyses, absence of ability to perfuse through the hepatic artery (P = 0.003), severe postoperative complications (P = 0.048) and >10 liver metastases (P = 0.006) adversely influenced overall survival and no adjuvant chemotherapy adversely influenced progression-free survival.


CONCLUSIONS
This is the first study to report prognostic factors for survival after IHP. Possibly, overall and disease-free survival can increase if preoperative screening is improved. In future studies on IHP, adjuvant chemotherapy should be considered.
van Iersel
L B J
LB
Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands. l.b.j.van_iersel@lumc.nl
Gelderblom
H
H
Vahrmeijer
A L
AL
van Persijn van Meerten
E L
EL
Tijl
F G J
FG
Putter
H
H
Hartgrink
H H
HH
Kuppen
P J K
PJ
Nortier
J W R
JW
Tollenaar
R A E M
RA
van de Velde
C J H
CJ
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan